2006-2016年英国当前哮喘患病率及吸入糖皮质激素治疗的变化:基于人群的队列研究
该研究利用2006-2016年英国电子医疗记录,估计当前哮喘患病率及吸入糖皮质激素(ICS)处方比例等。2016年总体患病率为6.5%(2006年为7.2%),45岁以下人群患病率下降,而ICS处方比例从65%升至80%。
要点
- 2016年英国当前哮喘总体患病率为6.5%,低于2006年的7.2%。
- 45岁以下人群患病率下降,5岁以下儿童降幅最大。
- ICS处方比例从2006年65%升至2016年80%,各年龄组均增加。
核心结论
- 哮喘在英国仍高度流行并构成显著医疗负担。
- 已诊断患者中ICS处方和急性发作治疗各年龄组均增加,可能反映初级保健中更积极的哮喘管理。
- 45岁以下人群患病率似有下降,尤其是5岁以下儿童。
研究设计与样本
- 基于英国电子医疗记录的人群队列研究,时间范围为2006-2016年。
- 按年份、性别和年龄组(<5、5-11、12-17、18-24、25-54和≥55岁)估计当前哮喘患病率。
- 同时评估ICS处方比例、附加哮喘治疗、急性发作治疗及其他哮喘照护指标。
主要发现
- 2016年总体当前哮喘患病率为6.5%,2006年为7.2%。
- 患病率在45岁以下人群中下降,5岁以下儿童患病率最低且绝对降幅最大。
- 2016年80%的当前哮喘患者接受ICS管理,2006年为65%,增加主要源于低剂量ICS的使用增加。
- 各年龄组附加哮喘治疗处方比例、初级保健中急性发作治疗比例以及年度哮喘评估或管理计划给予比例均增加。
- 住院急性发作随时间变化极小。
临床怎么用
- 研究提示初级保健中哮喘管理趋于更积极,ICS处方及急性发作治疗覆盖各年龄组增加。
- 对于45岁以下人群,尤其是5岁以下儿童,当前哮喘患病率呈下降趋势,临床需关注诊断与照护变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma is the most common respiratory disorder in the UK, yet we have incomplete knowledge on the prevalence of current disease, treatment and exacerbations.We used UK electronic healthcare records, 2006-2016, to estimate the prevalence of current asthma by year, sex and age (<5, 5-11, 12-17, 18-24, 25-54 and ≥55 years), and the proportion prescribed inhaled corticosteroids (ICS) and additional asthma therapy, treated for exacerbations and other asthma care markers.Overall current asthma prevalence was 6.5% in 2016 (7.2% in 2006). Prevalence fell in those aged <45 years. The lowest prevalence and largest absolute decrease was in children aged <5 years. In 2016, 80% of current asthma patients were managed on ICS (65% in 2006); this increase occurred in all age groups, primarily due to an increase in low-dose ICS. During this time there was an increase in all age groups in the proportion prescribed additional asthma therapy, treated for an exacerbation within primary care and given an annual asthma review or management plan. Hospitalised exacerbations showed minimal change over time.Asthma remains highly prevalent and a significant healthcare burden. In those with a diagnosis, there was an increase in ICS prescriptions and treatment of exacerbations across all age groups. This may reflect a trend towards more aggressive asthma management within primary care. An apparent decline in prevalence was observed in those aged <45 years, particularly in children aged <5 years.
引用
- Bloom CI, Saglani S, Feary J, et al. Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006-2016. Eur Respir J. 2019. PMID: 30765507. doi:10.1183/13993003.02130-2018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。